...
kzr-img

Kezar Life Sciences Inc, Common Stock

KZR

NAQ

$6.49

+$0.2

(3.18%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$45.89M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
48.66K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.22
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$5.2 L
$11.35 H
$6.49

About Kezar Life Sciences Inc, Common Stock

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameKZRSectorS&P500
1-Week Return-8.71%-3.39%-3.47%
1-Month Return-14.88%-3.25%-0.29%
3-Month Return9.13%-11.61%4.5%
6-Month Return-3.95%-5.89%6.91%
1-Year Return-25.35%2.65%23.79%
3-Year Return-95.73%0.56%28.43%
5-Year Return-79.24%34.63%83.64%
10-Year Return-96.46%94.78%185.94%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue----7.00M[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue1.30M1.54M1.51M1.02M1.07M[{"date":"2019-12-31","value":84.26,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":97.8,"profit":true},{"date":"2022-12-31","value":66.26,"profit":true},{"date":"2023-12-31","value":69.04,"profit":true}]
Gross Profit(1.30M)(1.54M)(1.51M)(1.02M)5.93M[{"date":"2019-12-31","value":-21.92,"profit":false},{"date":"2020-12-31","value":-26.02,"profit":false},{"date":"2021-12-31","value":-25.45,"profit":false},{"date":"2022-12-31","value":-17.24,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Gross Margin(Infinity%)(Infinity%)(Infinity%)(Infinity%)84.77%[{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Operating Expenses37.34M42.95M54.66M71.16M118.42M[{"date":"2019-12-31","value":31.53,"profit":true},{"date":"2020-12-31","value":36.27,"profit":true},{"date":"2021-12-31","value":46.16,"profit":true},{"date":"2022-12-31","value":60.09,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(37.34M)(42.95M)(54.66M)(71.16M)(105.24M)[{"date":"2019-12-31","value":-3734200000,"profit":false},{"date":"2020-12-31","value":-4295000000,"profit":false},{"date":"2021-12-31","value":-5465900000,"profit":false},{"date":"2022-12-31","value":-7116200000,"profit":false},{"date":"2023-12-31","value":-10523700000,"profit":false}]
Total Non-Operating Income/Expense4.51M2.42M58.00K5.85M12.45M[{"date":"2019-12-31","value":36.24,"profit":true},{"date":"2020-12-31","value":19.41,"profit":true},{"date":"2021-12-31","value":0.47,"profit":true},{"date":"2022-12-31","value":46.97,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(35.09M)(41.74M)(54.63M)(68.24M)(101.87M)[{"date":"2019-12-31","value":-3508700000,"profit":false},{"date":"2020-12-31","value":-4174200000,"profit":false},{"date":"2021-12-31","value":-5463000000,"profit":false},{"date":"2022-12-31","value":-6823900000,"profit":false},{"date":"2023-12-31","value":-10187000000,"profit":false}]
Income Taxes(3.56M)(2.75M)(1.35M)(2.92M)898.11K[{"date":"2019-12-31","value":-395.94,"profit":false},{"date":"2020-12-31","value":-306.42,"profit":false},{"date":"2021-12-31","value":-150.43,"profit":false},{"date":"2022-12-31","value":-325.46,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Income After Taxes(31.53M)(38.99M)(53.28M)(65.32M)(102.77M)[{"date":"2019-12-31","value":-3153100000,"profit":false},{"date":"2020-12-31","value":-3899000000,"profit":false},{"date":"2021-12-31","value":-5327900000,"profit":false},{"date":"2022-12-31","value":-6531600000,"profit":false},{"date":"2023-12-31","value":-10276810500,"profit":false}]
Income From Continuous Operations(35.09M)(41.74M)(54.63M)(68.24M)(87.79M)[{"date":"2019-12-31","value":-3508700000,"profit":false},{"date":"2020-12-31","value":-4174200000,"profit":false},{"date":"2021-12-31","value":-5463000000,"profit":false},{"date":"2022-12-31","value":-6823900000,"profit":false},{"date":"2023-12-31","value":-8779100000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(31.53M)(38.99M)(53.28M)(65.32M)(101.87M)[{"date":"2019-12-31","value":-3153100000,"profit":false},{"date":"2020-12-31","value":-3899000000,"profit":false},{"date":"2021-12-31","value":-5327900000,"profit":false},{"date":"2022-12-31","value":-6531600000,"profit":false},{"date":"2023-12-31","value":-10187000000,"profit":false}]
EPS (Diluted)(1.84)(0.97)(1.03)(1.01)(1.41)[{"date":"2019-12-31","value":-184,"profit":false},{"date":"2020-12-31","value":-97,"profit":false},{"date":"2021-12-31","value":-103,"profit":false},{"date":"2022-12-31","value":-101,"profit":false},{"date":"2023-12-31","value":-141,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

KZR
Cash Ratio 7.26
Current Ratio 7.65

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

KZR
ROA (LTM) -28.07%
ROE (LTM) -51.48%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

KZR
Debt Ratio Lower is generally better. Negative is bad. 0.18
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.82

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

KZR
Trailing PE NM
Forward PE NM
P/S (TTM) 6.56
P/B 0.34
Price/FCF NM
EV/R 0.00
EV/Ebitda 0.06

FAQs

What is Kezar Life Sciences Inc share price today?

Kezar Life Sciences Inc (KZR) share price today is $6.49

Can Indians buy Kezar Life Sciences Inc shares?

Yes, Indians can buy shares of Kezar Life Sciences Inc (KZR) on Vested. To buy Kezar Life Sciences Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in KZR stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Kezar Life Sciences Inc be purchased?

Yes, you can purchase fractional shares of Kezar Life Sciences Inc (KZR) via the Vested app. You can start investing in Kezar Life Sciences Inc (KZR) with a minimum investment of $1.

How to invest in Kezar Life Sciences Inc shares from India?

You can invest in shares of Kezar Life Sciences Inc (KZR) via Vested in three simple steps:

  • Click on Sign Up or Invest in KZR stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Kezar Life Sciences Inc shares
What is Kezar Life Sciences Inc 52-week high and low stock price?

The 52-week high price of Kezar Life Sciences Inc (KZR) is $11.35. The 52-week low price of Kezar Life Sciences Inc (KZR) is $5.2.

What is Kezar Life Sciences Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Kezar Life Sciences Inc (KZR) is

What is Kezar Life Sciences Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Kezar Life Sciences Inc (KZR) is 0.34

What is Kezar Life Sciences Inc dividend yield?

The dividend yield of Kezar Life Sciences Inc (KZR) is 0.00%

What is the Market Cap of Kezar Life Sciences Inc?

The market capitalization of Kezar Life Sciences Inc (KZR) is $45.89M

What is Kezar Life Sciences Inc’s stock symbol?

The stock symbol (or ticker) of Kezar Life Sciences Inc is KZR

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top